Gilbert Fuller Sells 1,057 Shares of USANA Health Sciences (NYSE:USNA) Stock

USANA Health Sciences, Inc. (NYSE:USNAGet Free Report) Director Gilbert Fuller sold 1,057 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $18.66, for a total value of $19,723.62. The transaction was disclosed in a document filed with the SEC, which is available through this link.

USANA Health Sciences Price Performance

USNA traded down $0.66 during trading hours on Tuesday, hitting $18.08. 29,553 shares of the stock were exchanged, compared to its average volume of 125,315. The stock has a 50-day simple moving average of $18.22 and a 200-day simple moving average of $19.49. USANA Health Sciences, Inc. has a 12 month low of $16.60 and a 12 month high of $38.32. The stock has a market cap of $333.76 million, a price-to-earnings ratio of 38.47, a price-to-earnings-growth ratio of 0.74 and a beta of 0.77.

USANA Health Sciences (NYSE:USNAGet Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.17. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.The firm had revenue of $250.22 million for the quarter, compared to analysts’ expectations of $240.99 million. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. Sell-side analysts expect that USANA Health Sciences, Inc. will post 2.12 EPS for the current year.

Institutional Trading of USANA Health Sciences

Hedge funds have recently made changes to their positions in the stock. Allianz Asset Management GmbH lifted its holdings in shares of USANA Health Sciences by 126.0% in the 3rd quarter. Allianz Asset Management GmbH now owns 47,203 shares of the company’s stock worth $1,300,000 after purchasing an additional 26,314 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of USANA Health Sciences by 382.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock worth $73,000 after purchasing an additional 1,901 shares during the last quarter. National Bank of Canada FI raised its stake in USANA Health Sciences by 166.6% during the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after acquiring an additional 1,201 shares in the last quarter. First Trust Advisors LP raised its stake in USANA Health Sciences by 17.7% during the 1st quarter. First Trust Advisors LP now owns 14,784 shares of the company’s stock valued at $258,000 after acquiring an additional 2,227 shares in the last quarter. Finally, Lazard Asset Management LLC acquired a new position in USANA Health Sciences during the 1st quarter worth $1,265,000. Institutional investors own 54.25% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Zacks Research cut USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 22nd. Wall Street Zen downgraded USANA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a report on Friday, March 27th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Reduce”.

Read Our Latest Stock Analysis on USNA

USANA Health Sciences Company Profile

(Get Free Report)

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.

Featured Stories

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.